Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-11-20 00:00:00 ET · period of report 2023-11-16 · accession 0000950170-23-065259 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-20 | 2023-11-16 | AMLX | Cohen Joshua B | Co-CEO, Dir | M - OptEx | $1.57 | +63.7K | 2.91M | +2% | +$100.0K |
| D | 2023-11-20 | 2023-11-16 | AMLX | Cohen Joshua B | Co-CEO, Dir | M - OptEx | $0.00 | -63.7K | 36.3K | -64% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-16 | M | A | 63,694 | $1.57 | 2,906,311 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-11-16 | M | D | 63,694 | $0.00 | 36,306 | D | $1.57 · — to 2025-02-26 | 63,694 Common Stock | (F1) 25,012 shares subject to such option vested and became exercisable on February 26, 2021, with the remaining shares vesting in monthly installments of 2,083 shares thereafter. |